Compare SDOT & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDOT | GRI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.3M |
| IPO Year | 2019 | 2020 |
| Metric | SDOT | GRI |
|---|---|---|
| Price | $0.28 | $2.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 14.5M | 41.3K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 490.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,929,137.00 | N/A |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 60.08 | N/A |
| 52 Week Low | $0.24 | $0.18 |
| 52 Week High | $13.02 | $6.70 |
| Indicator | SDOT | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 22.36 | 44.80 |
| Support Level | $0.24 | $2.15 |
| Resistance Level | $0.96 | $2.69 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 2.53 | 19.63 |
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.